Consider shorting aTyr Pharma (ATYR) ahead of its pivotal Phase 3 data release around the end of August, as a trial failure could cause the stock to drop over 90%. The quantum computing sector, including stocks like D-Wave (QBTS) and Rigetti (RGTI), is viewed as an over-hyped "micro bubble" and a potential shorting opportunity. Joby Aviation (JOBY) is also identified as a high-conviction short candidate based on the belief it is a "scam". On the long side, Abivax (ABVX) is presented as a bullish idea with a positive outlook. Lastly, be cautious with weight-loss drug stocks like Viking Therapeutics (VKTX), as the sector may face headwinds.

aTyr Pharma (ATYR)

• The speaker, Martin Shkreli, is extremely bearish on ATYR and has a significant short position. He refers to it as his primary focus, calling the company's lead drug "fake" and "dog shit." • He believes the stock could lose 90% of its value and is heading "right back to one" dollar. • The main catalyst is the upcoming Phase 3 trial data for its drug in pulmonary sarcoidosis, expected around the end of August.

The Bearish Thesis

• Flawed Mechanism of Action (MOA): - The drug targets a protein called Neuropylon 2 (NRP2). - Shkreli argues that NRP2 is a co-receptor that does not have its own signaling activity, making it a questionable drug target. - He claims the company discovered the drug's binding to this protein "by accident" and then created a "bullshit story" to explain its efficacy, which he finds highly suspect. • Weak Clinical Data: - He asserts the Phase 1/2 data is not good, showing no clear dose-response. The 1mg dose performed numerically worse than placebo on some measures. - He believes the trial results were skewed by a baseline imbalance, where healthier patients were coincidentally in the higher-dose groups, making the drug appear effective when it wasn't. - The company allegedly changed its primary endpoint after the trial because the placebo group performed best on the original endpoint (successful steroid taper). • Difficult Disease Area: - Sarcoidosis is described as a disease with a long history of clinical trial failures. Shkreli compares it to Alzheimer's, where many drugs have failed, suggesting it's an "intractable" disease that is not well understood. This makes any new drug a low-probability bet. • Company Incentives: - The speaker suggests that as a company with only one major drug, ATYR is incentivized to advance it to Phase 3 regardless of weak data to maintain a higher valuation and justify executive salaries.

Takeaways

• ATYR is presented as a high-conviction short opportunity based on a belief that its lead drug for sarcoidosis will fail its upcoming Phase 3 trial. • The primary catalyst is the Phase 3 data release, expected around the end of August. This is a binary event, meaning the stock could move dramatically in either direction based on the news. • For investors considering a short position, the speaker suggests a position size between 1% and 10% of their portfolio. He strongly advises that anyone new to shorting or biotech investing should start with a very small position, such as 1%, to manage the high risk. • The speaker dismisses bullish arguments from retail investors and sell-side analysts, believing they do not understand the science or are misinterpreting the data.

Quantum Computing Sector (D-Wave, Rigetti)

• The speaker is very bearish on the quantum computing sector, calling it a "micro bubble" that is poised to "pop". • He explicitly states to "short quantum" and mentions that stocks like QUBT (likely a reference to D-Wave, QBTS) are "good shorts". • He mentions D-Wave (QBTS) and Rigetti (RGTI) as being on the actively traded list and down on the day. • A caller mentions they shorted Rigetti and hedged with options.

Takeaways

• The quantum computing sector is viewed as over-hyped and a potential shorting opportunity. • Investors could consider short positions in quantum computing companies like D-Wave (QBTS) or Rigetti (RGTI), or potentially a sector-focused ETF if available. • This is a thematic short based on the belief that the sector's valuation is a "frothy" bubble that will deflate.

Joby Aviation (JOBY)

• The speaker has a strong bearish view on Joby. • He explicitly calls the company a "scam" and a "wild card, short Joby".

Takeaways

• JOBY is identified as a potential short based on the speaker's belief that the company is a "scam." • This is a high-conviction bearish call, though less detail was provided compared to ATYR.

Abivax (ABVX)

• The speaker is bullish on Abivax. • He mentions his Abivax position is up and that he is happy to see it performing well while other stocks are down. He states, "I like Abby Vax."

Takeaways

• ABVX is presented as a long idea. The speaker holds a position and has a positive outlook on the company.

Replimune (REPL)

• The speaker mentions he "sold some REPL, but I'm still in. Sold half." • This indicates he was long the stock and is taking some profits off the table.

Takeaways

• The speaker remains bullish on REPL but has reduced his position to lock in gains. • This could be an actionable insight for current holders to consider trimming a winning position while still maintaining some exposure for future upside.

UnitedHealth (UNH)

• The speaker expressed a clear negative sentiment, stating, "I don't like UNH."

Takeaways

• UNH is viewed with bearish sentiment. While no detailed thesis was provided, it's a stock the speaker would avoid or potentially short.

General Market & Sector Commentary

• Overall Market: The speaker notes the market has been "frothy" and was waiting for a reversal, but also acknowledges there is "a lot of dry powder" for fundraising in strong companies like Figma and OpenAI. He believes we are "still in a bull market" but that certain "micro bubbles" like quantum will pop without spoiling the entire market. • Biopharma Sector: Mentioned as a "defensive space" that tends to be solid in bad economic times. This suggests money could rotate into biopharma if the broader market weakens. • GLP-1 / Weight-Loss Drugs: A bearish comment was made about the sector following Novo Nordisk's (NVO) struggles. The speaker said, "it's over for... Viking, all those companies. If Novo can't even grow Zempic, you gotta have something special." This suggests headwinds for companies like Viking Therapeutics (VKTX).

Takeaways

• Be cautious of "frothy" momentum stocks, as they may be due for a correction. • The broader bull market may continue, but specific overvalued sectors (like quantum computing) are at high risk. • The biopharma sector could be a place to look for defensive investments during market downturns. • The weight-loss drug sector, including companies like Viking (VKTX), may face challenges if the market leader Novo Nordisk shows signs of slowing growth.

Quick Mentions

• Amazon (AMZN): Noted as being down 7% on "weak cloud results." This is a bearish data point for the company. • Apple (AAPL): Noted as being up 2% after "surprisingly good earnings." This is a bullish data point. • Nvidia (NVDA): Mentioned as a heavily traded stock. No strong directional view was given, just an observation of its high trading volume and minor daily price drop. • Coinbase (COIN): Noted as being down 11%, a significant drop. This is a bearish data point.